News Column

LifeWatch Results Q4 & FFY 2013

February 26, 2014

newsbox.ch

LifeWatch AG reports solid organic revenue growth in its monitoring services offering



Neuhausen am Rheinfall/Switzerland,February 27,2014- LifeWatch AG (SIX Swiss Exchange: LIFE), the leading providerof wireless telemedicine, has announced its unaudited results for the fourth quarter 2013 and full fiscal year 2013. The company reports strong growth in its monitoring services offering during the fourth quarter and full fiscal year 2013, and signed a total of 104 new or amended contracts during 2013. Total revenues in 2013 surged 13.3% to USD 90.77 million with a gross profit margin of 58.7%. Due to higher expenses, operating profitability failed to keep up with revenue growth, resulting in an EBITDA of USD 4.59 million in FFY 2013 compared with USD 8.35 million in FFY 2012. Extraordinary costs for legal and finance expenses, a provision, a write-off as well as a one-off payment to the former CEO amounted to USD 3.77 million, of which USD 3.04 million in the fourth quarter alone. Without these extraordinary items, an EBIT of USD 4.71 million with an EBIT margin of 5.2% would have been achieved in FFY 2013. Net income for the reporting year reached USD 6.03 million compared to a net loss of USD 0.37 million in the previous year.


LifeWatch made significant progress during FFY 2013. U.S.-based LifeWatch Services, Inc. was able to sign a total of 104 new or amended contracts during the year. Our monitoring service revenues achieved higher growth in 2013, due to a focused sales strategy and the provision of improved resources, tools and training to our sales force. We have built on our core competencies which highlight the clinical benefits and diagnostic yield associated with LifeWatch products and services, which we believe aligns with the evolving healthcare landscape to insure the appropriate use and application of all diagnostics. Our offerings support the continuum of care through interoperability with our customized EMR/EHR solutions and clinical reporting.


Due to higher operating expenses, profitability failed to keep up with revenue growth. Our expansion and diversification strategies and the hiring of additional sales representatives across the organization resulted in higher Sales and Marketing expenses. General and Administration expenses rose by USD 6.42 million in 2013 as a result of both higher corporate costs and extraordinary expenses. Extraordinary costs of USD 3.77 million include legal and finance expenses amounting to USD 1.36 million, a one-off payment to the former CEO Dr. Yacov Geva amounting to USD 1.34 million, a provision of USD 0.85 million and a one-off inventory write-off in the amount of USD 0.22 million.


Revenues

Q4 2013: revenues reached USD 24.41 million, corresponding to growth of 21.6% over Q4 2012. Monitoring services contributed over 98.9% to Q4 2013 revenues.


FFY 2013: revenues reached USD 90.77 million, reflecting growth of 13.3% from FFY 2012 revenues. Monitoring services contributed USD 89.21 million, up 12.2% on the previous year.


Gross Profit

Q4 2013: gross profit came in at USD 14.16 million with a margin of 58.0%, compared with a gross profit of USD 11.47 million and a margin of 57.1% in Q4 2012.


FFY 2013: gross profit reached USD 53.32 million with a margin of 58.7%, compared with FFY 2012 gross profit of USD 46.03 million and a margin of 57.5%.


Operating Expenses

Q4 2013 breakdown of operating expenses:

Research and Development (R&D) expenses amounted to USD 2.01 million or 8.2% of revenues, compared with R&D expenses of USD 1.87 million, or 9.3% of revenues, in Q4 2012. The R&D expenses are directly associated with the investments in the LifeWatch V platform and the Vital Signs Patch.Sales and Marketing (S&M) expenses came in at USD 5.29 million or 21.7% of revenues, compared with USD 4.14 million or 20.7% of revenues in Q4 2012. The increased expenses are related to our expansion and diversification strategies.General and Administration (G&A) expenses increased to USD 9.36 million or 38.4% of revenues, compared with G&A expenses of USD 4.60 million or 22.9% of revenues in Q4 2012.


FFY 2013 breakdown of the operating expenses:

Research and Development (R&D) expenses were USD 7.75 million or 8.5% of revenues, compared with USD 6.91 million or 8.6% of revenues for FFY 2012. The R&D expenses are related to the investments in the Vital Signs Patch and LifeWatch V health smartphone products mentioned previously.Sales and Marketing (S&M) expenses stood at USD 19.55 million or 21.5% of revenues, compared with S&M expenses of USD 16.57 million or 20.7% of revenues in FFY 2012. The increase in S&M expenditures reflects the hiring of additional sales representatives across the organization.General and Administration (G&A) expenses were USD 25.07 million or 27.6% of revenues, compared with G&A expenses of USD 18.65 million or 23.3% of revenues in the previous year.


Operating result

Q4 2013: LBIT was USD 2.51 million, compared with an EBIT of USD 0.85 million in Q4 2012. The LBITDA reached USD 1.31 million, compared with an EBITDA of USD 1.78 million and a margin of 8.9% in Q4 2012.


FFY 2013: EBIT was USD 0.94 million with a margin of 1.0%, compared with an EBIT of USD 4.37 million and a margin of 5.5% reported in FFY 2012. The EBITDA amounted to USD 4.59 million and a margin of 5.1%, compared with an EBITDA of USD 8.35 million and a margin of 10.4% in FFY 2012.


Net Income/Loss

Q4 2013: net loss was USD 3.39 million, compared with net income of USD 0.47 million in Q4 2012. The fully-diluted loss per share was USD 0.26 in Q4 2013, compared with earnings per share of USD 0.03 in Q4 2012.


FFY 2013: net income was USD 6.03 million, compared with a net loss of USD 0.37 million in FFY 2012. The fully-diluted earnings per share were USD 0.45, compared with a loss per share of USD 0.03 in FFY 2012.


Operating Cash Flow

Q4 2013: LifeWatch operations provided cash in the amount of USD 0.01 million, compared with USD 1.13 million in cash used in Q4 2012. The balance of cash, cash equivalents, marketable securities and structures amounted to USD 10.23 million at the end of the quarter, compared with USD 5.95 million at the end of Q4 2012.


FFY 2013: LifeWatch operations provided cash in the amount of USD 8.26 million, compared with USD 7.75 million used in operations in FFY 2012. The balance of cash, cash equivalents, marketable securities and structures amounted to USD 10.23 million at the end of the year, compared with USD 5.95 million at the end of 2012.


Outlook

The new Board of Directors initiated an in-depth analysis of LifeWatch's current and future strategy. The results will be presented prior to the next shareholders' meeting. The Board continues to believe in LifeWatch's strong growth potential based on both its qualified, highly motivated staff and the innovative technology platform.


Key Figures for Q4 2013 and Full Fiscal Year 2013(unaudited, in USD million)






Q4 2013



Q4 2012



FFY 2013



FFY 2012



Revenues



24.41



20.07



90.77



80.11



Gross profit



14.16



11.47



53.32



46.03



As % of revenues



58.0%



57.1%



58.7%



57.5%



EBITDA / (LBITDA)



(1.31)



1.78



4.59



8.35



As % of revenues



N/A



8.9%



5.1%



10.4%



EBIT / (LBIT)



(2.51)



0.85



0.94



4.37



As % of revenues



N/A



4.2%



1.0%



5.5%



Net income / (loss)



(3.39)



0.47



6.03



(0.37)



As % of revenues



N/A



2.3%



6.6%



N/A



Total fixed assets, net



12.05



7.84



12.05



7.84



Total equity



41.55



34.93



41.55



34.93



Employees at the end of period



544



492



544



492





For further questions:

LifeWatch AG

c/o Dynamics Group, Philippe Blangey

Phone: +41 43 268 32 35

E-mail: investor-relations@lifewatch.com



About LifeWatch AG:

LifeWatch AG, headquartered in Neuhausen am Rheinfall and listed on SIX Swiss Exchange (LIFE),

Switzerland, is the leading healthcare technology and solution company, specializing in advanced telehealth systems and wireless remote patient monitoring services. LifeWatch services cater to individuals, ranging from high-risk and chronically ill patients to consumers of health and wellness products. LifeWatch AG has operative subsidiaries in the United States, in Switzerland and in Israel, and is the parent company of LifeWatch Services Inc., and LifeWatch Technologies, Ltd.LifeWatch Services, Inc. is a leading U.S.-based provider of cardiac monitoring services and home sleep testing of Obstructive Sleep Apnea (OSA). LifeWatch Technologies Ltd., based in Israel, is a leading developer and manufacturer of telemedicine products. The company is planning to introduce the LifeWatch V, an Android-based smartphone with medical sensors and apps that uses a cloud-based service platform. For additional information, please visit www.lifewatch.com.



Sign upfor customized e-mail alerts and documentation requests at

http://www.irlifewatch.com/alert-service.aspx



This press release includes forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding future results of operations and financial position, the business strategy, and plans and objectives for future operations, are forward-looking statements. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect" and similar expressions are intended to identify forward-looking statements. LifeWatch AG has based these forward-looking statements largely on current expectations and projections about future events and financial trends that it believes may affect the financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances described may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. All forward-looking statements are based only on data available to LifeWatch AG at the time of the issue of this press release. LifeWatch AG does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.


THIS PRESS RELEASE IS NOT BEING ISSUED IN THE UNITED STATES OF AMERICA AND SHOULD NOT BE DISTRIBUTED TO UNITED STATES PERSONS OR PUBLICATIONS WITH A GENERAL CIRCULATION IN THE UNITED STATES. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OF SECURITIES OF LIFEWATCH AG OR ANY OF ITS SUBSIDIARIES FOR SALE IN THE UNITED STATES, OR AN INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY SECURITIES OF LIFEWATCH AG OR ITS SUBSIDIARIES IN THE UNITED STATES.IN ADDITION, THE SECURITIES OF LIFEWATCH AG AND ITS SUBSIDIARIES HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD OR DELIVERED WITHIN THE UNITED STATES OR TO U.S. PERSONS ABSENT FROM REGISTRATION UNDER OR AN APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE UNITED STATES SECURITIES LAWS. ANY PUBLIC OFFERING OF SECURITIES TO BE MADE IN THE UNITED STATES WILL BE MADE BY MEANS OF A PROSPECTUS THAT MAY BE OBTAINED FROM LIFEWATCH AG OR ITS SUBSIDIARIES, AS APPLICABLE, AND WILL CONTAIN DETAILED INFORMATION ABOUT THE ISSUER AND ITS MANAGEMENT AS WELL AS FINANCIAL STATEMENTS OF THE ISSUER.







PDF of press release







Provider

Channel

Contact
Tensid Ltd., Switzerland

www.tensid.ch





newsbox.ch

www.newsbox.ch





Provider/Channel related enquiries

marco@tensid.ch

+41 41 763 00 50


For more stories on investments and markets, please see HispanicBusiness' Finance Channel



Source: Tensid Regulatory


Story Tools